
Manuela Pilleri

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7427282/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effects of Bilateral Subthalamic Stimulation on Cognitive Function in Parkinson Disease. Archives of Neurology, 2001, 58, 1223.	4.5	226
2	Identification of circulating microRNAs for the differential diagnosis of Parkinson's disease and Multiple System Atrophy. Frontiers in Cellular Neuroscience, 2014, 8, 156.	3.7	150
3	Bilateral subthalamic nucleus stimulation and quality of life in advanced Parkinson's disease. Movement Disorders, 2002, 17, 372-377.	3.9	148
4	Validation of the Italian version of the Movement Disorder Society—Unified Parkinson's Disease Rating Scale. Neurological Sciences, 2013, 34, 683-687.	1.9	123
5	Bilateral subthalamic stimulation monotherapy in advanced Parkinson's disease: Longâ€ŧerm followâ€up of patients. Movement Disorders, 2002, 17, 125-132.	3.9	89
6	Patterns of cortical thickness associated with impulse control disorders in Parkinson's disease. Movement Disorders, 2015, 30, 688-695.	3.9	83
7	Cognitive profiling of Parkinson disease patients with mild cognitive impairment and dementia. Parkinsonism and Related Disorders, 2014, 20, 394-399.	2.2	82
8	Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease. Movement Disorders, 2004, 19, 1463-1469.	3.9	75
9	Cognitive and MRI correlates of orthostatic hypotension in Parkinson's disease. Journal of Neurology, 2013, 260, 253-259.	3.6	62
10	Hardware-related infections after deep brain stimulation surgery: review of incidence, severity and management in 212 single-center procedures in the first year after implantation. Acta Neurochirurgica, 2011, 153, 2337-2341.	1.7	56
11	Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease. Expert Opinion on Drug Safety, 2015, 14, 281-294.	2.4	53
12	Diagnostic and screening power of neuropsychological testing in detecting mild cognitive impairment in Parkinson's disease. Journal of Neural Transmission, 2013, 120, 627-633.	2.8	48
13	[¹²³ I]FPâ€CIT SPET imaging in drugâ€induced Parkinsonism. Movement Disorders, 2008, 23, 1825-1829.	3.9	47
14	Targeting of the Subthalamic Nucleus for Deep Brain Stimulation: A Survey Among Parkinson Disease Specialists. World Neurosurgery, 2017, 99, 41-46.	1.3	45
15	Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up. Parkinsonism and Related Disorders, 2017, 38, 90-92.	2.2	44
16	Switching from constant voltage to constant current in deep brain stimulation: a multicenter experience of mixed implants for movement disorders. European Journal of Neurology, 2016, 23, 190-195.	3.3	41
17	Subthalamic Stimulation Improves Quality of Life of Patients Aged 61 Years or Older With Short Duration of Parkinson's Disease. Neuromodulation, 2018, 21, 532-540.	0.8	26
18	Successful subthalamic stimulation in genetic Parkinson's disease caused by duplication of the α-synuclein gene. Journal of Neurology, 2012, 259, 165-167.	3.6	25

Manuela Pilleri

#	Article	IF	CITATIONS
19	Heart rate circadian profile in the differential diagnosis between Parkinson disease and multiple system atrophy. Parkinsonism and Related Disorders, 2014, 20, 217-221.	2.2	25
20	Levodopa–carbidopa intrajejunal gel in advanced Parkinson disease with "on―freezing of gait. Neurological Sciences, 2015, 36, 1683-1686.	1.9	25
21	Novel levodopa formulations in the treatment of Parkinson's disease. Expert Review of Neurotherapeutics, 2014, 14, 143-149.	2.8	24
22	Overground robot assisted gait trainer for the treatment of drug-resistant freezing of gait in Parkinson disease. Journal of the Neurological Sciences, 2015, 355, 75-78.	0.6	24
23	Idiopathic delayed-onset edema surrounding deep brain stimulation leads: Insights from a case series and systematic literature review. Parkinsonism and Related Disorders, 2016, 32, 108-115.	2.2	22
24	Four year follow-up study after unilateral pallidotomy in advanced Parkinson's disease. Journal of Neurology, 2002, 249, 1671-1677.	3.6	17
25	Brain impedance variation of directional leads implanted in subthalamic nuclei of Parkinsonian patients. Clinical Neurophysiology, 2019, 130, 1562-1569.	1.5	10
26	The MTHFR C677T polymorphism modifies age at onset in Parkinson's disease. Neurological Sciences, 2014, 35, 73-77.	1.9	9
27	Levodopa–carbidopa intrajejunal infusion in Parkinson's disease: untangling the role of age. Journal of Neurology, 2021, 268, 1728-1737.	3.6	9
28	Effects of rotigotine on Parkinson's disease-related sleep disturbances. Expert Opinion on Pharmacotherapy, 2013, 14, 2571-2580.	1.8	7
29	Deep brain stimulation in Parkinson's disease: A multicentric, long-term, observational pilot study. Journal of the Neurological Sciences, 2019, 405, 116411.	0.6	6
30	ls there room for new non-dopaminergic treatments in Parkinson's disease?. Journal of Neural Transmission, 2013, 120, 349-352.	2.8	5
31	Peri-electrode edema after bilateral subthalamic deep brain stimulation for Parkinson's disease. Journal of Neurosurgical Sciences, 2017, 62, 103-105.	0.6	1